Compare Stocks: VTYX, VKTX, DNLI, and RLAY

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
DNLI Denali Therapeutics	$25.00 +0.7%	$23.63	$12.58 ▼ $27.30	$3.94B	1.01	1.78 million shs	1.56 million shs
RLAY Relay Therapeutics	$19.94 +0.9%	$17.83	$3.15 ▼ $20.79	$4.33B	1.69	2.18 million shs	2.67 million shs
VKTX Viking Therapeutics	$34.44 +0.5%	$34.40	$22.96 ▼ $43.15	$4.00B	0.69	1.93 million shs	1.62 million shs
VTYX Ventyx Biosciences	$14.00	$13.98	$0.78 ▼ $25.00	$1.00B	1.26	3.32 million shs	5.45 million shs

10 Best Stocks to Own - Summer 2026

Enter your email address and we’ll send you MarketBeat’s list of ten stocks set to soar in Summer 2026, despite the threat of tariffs and what's happening in Iran. These ten stocks are incredibly resilient and are likely to thrive in any economic environment.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
DNLI Denali Therapeutics	+0.68%	+7.99%	-2.65%	+28.47%	+79.08%
RLAY Relay Therapeutics	+0.86%	+6.18%	-0.30%	+54.22%	+519.25%
VKTX Viking Therapeutics	+0.53%	+5.61%	-11.37%	+9.96%	-9.11%
VTYX Ventyx Biosciences	0.00%	0.00%	0.00%	0.00%	+398.22%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
DNLI Denali Therapeutics	$25.00 +0.7%	$23.63	$12.58 ▼ $27.30	$3.94B	1.01	1.78 million shs	1.56 million shs
RLAY Relay Therapeutics	$19.94 +0.9%	$17.83	$3.15 ▼ $20.79	$4.33B	1.69	2.18 million shs	2.67 million shs
VKTX Viking Therapeutics	$34.44 +0.5%	$34.40	$22.96 ▼ $43.15	$4.00B	0.69	1.93 million shs	1.62 million shs
VTYX Ventyx Biosciences	$14.00	$13.98	$0.78 ▼ $25.00	$1.00B	1.26	3.32 million shs	5.45 million shs

10 Best Stocks to Own - Summer 2026

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
DNLI Denali Therapeutics	+0.68%	+7.99%	-2.65%	+28.47%	+79.08%
RLAY Relay Therapeutics	+0.86%	+6.18%	-0.30%	+54.22%	+519.25%
VKTX Viking Therapeutics	+0.53%	+5.61%	-11.37%	+9.96%	-9.11%
VTYX Ventyx Biosciences	0.00%	0.00%	0.00%	0.00%	+398.22%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
DNLI Denali Therapeutics	2.75	Moderate Buy	$35.92	43.67% Upside
RLAY Relay Therapeutics	2.86	Moderate Buy	$25.58	28.30% Upside
VKTX Viking Therapeutics	2.67	Moderate Buy	$97.88	184.19% Upside
VTYX Ventyx Biosciences	1.89	Reduce	$14.00	N/A

Current Analyst Ratings Breakdown

Latest VTYX, VKTX, DNLI, and RLAY Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
8/10/2026	RLAY Relay Therapeutics	Citigroup Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Market Outperform
8/10/2026	RLAY Relay Therapeutics	Citizens Jmp Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Market Outperform	$21.00 ➝ $26.00
8/7/2026	DNLI Denali Therapeutics	UBS Group Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Buy	$25.00 ➝ $34.00
8/7/2026	DNLI Denali Therapeutics	Robert W. Baird Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Set Price Target		$34.00
8/7/2026	RLAY Relay Therapeutics	Barclays Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Overweight	$27.00 ➝ $30.00
8/7/2026	RLAY Relay Therapeutics	Guggenheim Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy
7/30/2026	VKTX Viking Therapeutics	Canaccord Genuity Group Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Buy	$107.00 ➝ $114.00
7/23/2026	DNLI Denali Therapeutics	Morgan Stanley Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Overweight	$35.00 ➝ $36.00
7/22/2026	RLAY Relay Therapeutics	Zacks Research Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Hold ➝ Strong Sell
7/21/2026	RLAY Relay Therapeutics	The Goldman Sachs Group Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Buy	$22.00 ➝ $31.00
7/20/2026	VKTX Viking Therapeutics	Zacks Research Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Hold ➝ Strong Sell

(Data available from 8/11/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
DNLI Denali Therapeutics	$330.53M	12.00	N/A	N/A	$6.91 per share	3.62
RLAY Relay Therapeutics	$15.35M	284.67	N/A	N/A	$3.27 per share	6.10
VKTX Viking Therapeutics	N/A	N/A	N/A	N/A	$5.65 per share	N/A
VTYX Ventyx Biosciences	N/A	N/A	N/A	N/A	$3.59 per share	N/A

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
DNLI Denali Therapeutics	-$512.54M	-$2.84	N/A	N/A	N/A	N/A	-55.27%	-44.24%	N/A
RLAY Relay Therapeutics	-$276.48M	-$1.57	N/A	N/A	N/A	N/A	-47.23%	-43.10%	N/A
VKTX Viking Therapeutics	-$359.64M	-$4.66	N/A	N/A	N/A	N/A	-94.56%	-82.75%	10/28/2026 (Estimated)
VTYX Ventyx Biosciences	-$135.12M	-$1.50	N/A	N/A	N/A	N/A	-48.11%	-43.89%	N/A

Latest VTYX, VKTX, DNLI, and RLAY Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/6/2026	Q2 2026	DNLI Denali Therapeutics	-$0.5131	-$0.68	-$0.1670	-$0.68	$2.15 million	$3.60 million
8/6/2026	Q2 2026	RLAY Relay Therapeutics	-$0.3911	-$0.41	-$0.0189	-$0.41	$0.96 million	$0.35 million
7/29/2026	Q2 2026	VKTX Viking Therapeutics	-$1.21	-$1.10	+$0.11	-$1.10	N/A	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	5-Year Annualized Dividend Growth	Payout Ratio	Years of Consecutive Growth
DNLI Denali Therapeutics	N/A	N/A	N/A	N/A	N/A
RLAY Relay Therapeutics	N/A	N/A	N/A	N/A	N/A
VKTX Viking Therapeutics	N/A	N/A	N/A	N/A	N/A
VTYX Ventyx Biosciences	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
DNLI Denali Therapeutics	0.01	8.37	8.32
RLAY Relay Therapeutics	N/A	22.13	22.13
VKTX Viking Therapeutics	N/A	4.72	4.72
VTYX Ventyx Biosciences	N/A	17.86	17.86

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
DNLI Denali Therapeutics	92.92%
RLAY Relay Therapeutics	96.98%
VKTX Viking Therapeutics	76.03%
VTYX Ventyx Biosciences	97.88%

Insider Ownership

Company	Insider Ownership
DNLI Denali Therapeutics	9.70%
RLAY Relay Therapeutics	5.04%
VKTX Viking Therapeutics	5.30%
VTYX Ventyx Biosciences	14.49%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
DNLI Denali Therapeutics	430	158.71 million	143.32 million	Optionable
RLAY Relay Therapeutics	330	219.14 million	208.10 million	Optionable
VKTX Viking Therapeutics	20	116.65 million	110.47 million	Optionable
VTYX Ventyx Biosciences	30	71.76 million	61.36 million	Optionable

VTYX, VKTX, DNLI, and RLAY Headlines

Recent News About These Companies

Ventyx Biosciences Shareholders Approve Merger With Eli Lilly

June 12, 2026 | theglobeandmail.com

Ventyx Biosciences, Inc. Investigated by the Portnoy Law Firm

April 29, 2026 | globenewswire.com

Ventyx Biosciences Investor Alert: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Ventyx Biosciences, Inc. - VTYX

February 5, 2026 | businesswire.com

Assessing Ventyx Biosciences (VTYX) Valuation After Sharp Share Price Momentum And A High P/B Multiple

January 26, 2026 | finance.yahoo.com

Ventyx Biosciences Investor Alert: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Ventyx Biosciences, Inc. - VTYX

January 23, 2026 | prnewswire.com

Halper Sadeh LLC Encourages VTYX and SNCY Shareholders to Contact the Firm to Discuss Their Rights

January 21, 2026 | globenewswire.com

Halper Sadeh LLC Encourages VTYX, PEN, CWAN Shareholders to Contact the Firm to Discuss Their Rights

January 15, 2026 | caledonianrecord.comC

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Ventyx Biosciences, Inc. - VTYX

January 15, 2026 | prnewswire.com

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Ventyx Biosciences, Inc. - VTYX

January 13, 2026 | globenewswire.com

Halper Sadeh LLC Encourages VTYX, ONTF, FFIC, OCFC Shareholders to Contact the Firm to Discuss ...

January 13, 2026 | caledonianrecord.comC

LifeSci Capital Sticks to Its Hold Rating for Ventyx Biosciences (VTYX)

January 12, 2026 | theglobeandmail.com

UBS downgrades Ventyx Biosciences (VTYX)

January 10, 2026 | msn.com

Oppenheimer downgrades Ventyx Biosciences (VTYX)

January 9, 2026 | msn.com

Ventyx Biosciences Investor Alert: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Ventyx Biosciences, Inc. - VTYX

January 8, 2026 | prnewswire.com

INVESTIGATION ALERT: Edelson Lechtzin LLP Announces an Investigation of Ventyx Biosciences, Inc. (NASDAQ: VTYX) and Encourages Investors with Substantial Losses or Witnesses with Relevant Information to Contact the Firm

January 8, 2026 | prnewswire.com

Lilly confirms bid to acquire Ventyx Biosciences

January 8, 2026 | thepharmaletter.comT

Canaccord Genuity downgrades Ventyx Biosciences (VTYX)

January 8, 2026 | msn.com

SHAREHOLDER NOTICE: Brodsky & Smith Announces an Investigation of Ventyx Biosciences, Inc. (VTYX)

January 8, 2026 | newsfilecorp.comN

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Ventyx Biosciences, Inc. - VTYX

January 8, 2026 | prnewswire.com

VTYX Stock Alert: Halper Sadeh LLC is Investigating Whether the Sale of Ventyx Biosciences, Inc. is Fair to Shareholders

January 8, 2026 | businesswire.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

VTYX, VKTX, DNLI, and RLAY Company Descriptions

Denali Therapeutics NASDAQ:DNLI

$25.00 +0.17 (+0.68%)

Closing price 08/10/2026 04:00 PM Eastern

Extended Trading

$25.00 0.00 (-0.01%)

As of 05:06 AM Eastern

Denali Therapeutics Inc., a biopharmaceutical company, develops a portfolio of product candidates engineered to cross the blood-brain barrier for neurodegenerative diseases and lysosomal storage diseases in the United States. The company's transport vehicle (TV)-enabled programs include DNL310 ETV, an IDS enzyme replacement therapy program for MPS II; TAK-594/DNL593 which is in Phase 1/II for frontotemporal dementia-granulin; DNL126 program for MPS IIIA; and DNL622 for MPS I, as well as other preclinical programs that target amyloid beta and HER2. Its brain-penetrant small molecule programs comprise BIIB122/DNL151 LRRK2 inhibitor program for Parkinson's disease; SAR443820/DNL788 RIPK1 inhibitor program for CNS disease; DNL343 eIF2B Activator program for amyotrophic lateral sclerosis; and SAR443122/DNL758 RIPK1 inhibitor program for peripheral inflammatory diseases. It also provides early stage program include TAK-594/DNL593 program for FTD-GRN; DNL126 program for MPS IIIA, a Sanfilippo Syndrome A; DNL622 for MPS I which is Hurler syndrome; Antibody Transport Vehicle Amyloid beta program; Oligonucleotide Transport Vehicle platform, a novel class of biotherapeutics to address the root cause of diseases through modulation of gene expression; and other TV-enabled discovery programs. The company has collaboration agreements with Biogen MA Inc. and Biogen International GmbH; Genzyme Corporation; Takeda Pharmaceutical Company Limited; F-star Gamma Limited, F-star Biotechnologische Forschungs-und Entwicklungsges m.b.H, and F-star Biotechnology Limited; and Genentech, Inc. The company was formerly known as SPR Pharma Inc. and changed its name to Denali Therapeutics Inc. in March 2015. Denali Therapeutics Inc. was incorporated in 2013 and is headquartered in South San Francisco, California.

Relay Therapeutics NASDAQ:RLAY

$19.94 +0.17 (+0.86%)

Closing price 08/10/2026 04:00 PM Eastern

Extended Trading

$19.93 -0.01 (-0.07%)

As of 05:06 AM Eastern

Relay Therapeutics, Inc. operates as a clinical-stage precision medicines company. It engages in transforming the drug discovery process with an initial focus on enhancing small molecule therapeutic discovery in targeted oncology and genetic disease indications. The company's lead product candidates include RLY-4008, an oral small molecule inhibitor of fibroblast growth factor receptor 2 (FGFR2), which is in a first-in-human clinical trial for patients with advanced or metastatic FGFR2-altered solid tumors; RLY-2608, a lead mutant-PI3Ka inhibitor program that targets phosphoinostide 3 kinase alpha; and Migoprotafib (GDC-1971), an oral, small molecule, potent and selective inhibitor of the protein tyrosine phosphatase SHP2 that binds and stabilizes Src homology region 2 domain-containing phosphatase-2 (SHP2) as a monotherapy in patients with advanced or metastatic solid tumors. In addition, it has collaboration and license agreements with D. E. Shaw Research, LLC to research certain biological targets through the use of D. E. Shaw Research computational modeling capabilities focused on analysis of protein motion to develop and commercialize compounds and products directed to such targets; and Genentech, Inc. for the development and commercialization of GDC-1971. The company was formerly known as Allostery, Inc. and changed its name to Relay Therapeutics, Inc. in December 2015. Relay Therapeutics, Inc. was incorporated in 2015 and is headquartered in Cambridge, Massachusetts.

Viking Therapeutics NASDAQ:VKTX

$34.44 +0.18 (+0.53%)

Closing price 08/10/2026 04:00 PM Eastern

Extended Trading

$34.68 +0.24 (+0.70%)

As of 05:11 AM Eastern

Viking Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of novel therapies for metabolic and endocrine disorders. The company's lead drug candidate is VK2809, an orally available tissue and receptor-subtype selective agonist of the thyroid hormone receptor beta (TRß), which is in Phase IIb clinical trials to treat patients with biopsy-confirmed non-alcoholic steatohepatitis, as well as NAFLD. It also develops VK5211, an orally available non-steroidal selective androgen receptor modulator that is in Phase II clinical trials for the treatment of patients recovering from non-elective hip fracture surgery; VK0612, an orally available Phase IIb-ready drug candidate for type 2 diabetes; VK2735, a novel dual agonist of the glucagon-like peptide, which is in Phase 1 SAD/MAD clinical trial, and VK0214, an orally available tissue and receptor-subtype selective agonist of the TRß for X-linked adrenoleukodystrophy. The company was incorporated in 2012 and is headquartered in San Diego, California.

Ventyx Biosciences NASDAQ:VTYX

Ventyx Biosciences, Inc., a clinical-stage biopharmaceutical company, develops small molecule product candidates to address a range of inflammatory diseases. The company's lead clinical product candidate is VTX958, a selective allosteric tyrosine kinase type 2 inhibitor for psoriasis, psoriatic arthritis, and Crohn's disease. It is also developing VTX002, a sphingosine 1 phosphate receptor modulator that is in Phase II clinical trials for the treatment of ulcerative colitis; and VTX2735, a peripheral-targeted NOD-like receptor protein 3 inflammasome inhibitor to treat patients with cryopyrin-associated periodic syndrome. In addition, the company develops VTX3232, a CNS-penetrant NLRP3 inhibitor. Ventyx Biosciences, Inc. was incorporated in 2018 and is based in San Diego, California.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest VTYX, VKTX, DNLI, and RLAY Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest VTYX, VKTX, DNLI, and RLAY Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

VTYX, VKTX, DNLI, and RLAY Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

VTYX, VKTX, DNLI, and RLAY Company Descriptions

Denali Therapeutics NASDAQ:DNLI

Relay Therapeutics NASDAQ:RLAY

Viking Therapeutics NASDAQ:VKTX

Ventyx Biosciences NASDAQ:VTYX

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest VTYX, VKTX, DNLI, and RLAY Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest VTYX, VKTX, DNLI, and RLAY Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

VTYX, VKTX, DNLI, and RLAY Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

VTYX, VKTX, DNLI, and RLAY Company Descriptions

Denali Therapeutics NASDAQ:DNLI

Relay Therapeutics NASDAQ:RLAY

Viking Therapeutics NASDAQ:VKTX

Ventyx Biosciences NASDAQ:VTYX

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools